{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:25:39Z","timestamp":1760909139073,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s10072-018-3550-8","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T09:00:29Z","timestamp":1535706029000},"page":"2107-2113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis"],"prefix":"10.1007","volume":"39","author":[{"given":"Hossein","family":"Pakdaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koroush","family":"Gharagozli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Ashrafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hosein","family":"Delavar Kasmaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6157-5535","authenticated-orcid":false,"given":"Ali","family":"Amini Harandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"3550_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.neuro.30.051606.094313","volume":"31","author":"BD Trapp","year":"2008","unstructured":"Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247\u2013269","journal-title":"Annu Rev Neurosci"},{"key":"3550_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R (2007) The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 10:54\u201360","journal-title":"Value Health"},{"key":"3550_CR3","first-page":"101","volume":"29","author":"RJ Pokorski","year":"1997","unstructured":"Pokorski RJ (1997) Long-term survival experience of patients with multiple sclerosis. J Insur Med 29:101\u2013106","journal-title":"J Insur Med"},{"key":"3550_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2174\/157015911796557911","volume":"9","author":"I Loma","year":"2011","unstructured":"Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9:409\u2013416","journal-title":"Curr Neuropharmacol"},{"key":"3550_CR5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1212\/WNL.43.4.662","volume":"43","author":"D Paty","year":"1993","unstructured":"Paty D, Li DB (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662\u2013667","journal-title":"Neurology"},{"key":"3550_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"LD Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285\u2013294","journal-title":"Ann Neurol"},{"key":"3550_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1212\/01.wnl.0000237994.95410.ce","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos L, Traboulsee A, Constantinescu C, Er\u00e4linna J-P, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B (2006) Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67:944\u2013953","journal-title":"Neurology"},{"key":"3550_CR8","first-page":"30","volume":"68","author":"M Etemadifar","year":"2010","unstructured":"Etemadifar M, Mazdeh M, Torabi HR, Ghaffarpour M, Azimian M, Salami S, Shahkarami SMA (2010) A report of multiple sclerosis patients treated by CinnoVex\u2122 in Iran. Tehran Univ Med J 68:30\u201336","journal-title":"Tehran Univ Med J"},{"key":"3550_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5402\/2012\/786526","volume":"2012","author":"R Abolfazli","year":"2012","unstructured":"Abolfazli R, Hosseini A, Gholami K, Javadi M, Torkamandi H, Emami S (2012) Quality of life assessment in patients with multiple sclerosis receiving interferon beta-1a: a comparative longitudinal study of Avonex and its biosimilar CinnoVex. ISRN Neurol 2012:1\u20136","journal-title":"ISRN Neurol"},{"key":"3550_CR10","doi-asserted-by":"crossref","first-page":"543","DOI":"10.18553\/jmcp.2009.15.7.543","volume":"15","author":"L Goldberg","year":"2009","unstructured":"Goldberg L, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (2009) Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 15:543\u2013555","journal-title":"J Manag Care Pharm"},{"key":"3550_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"K Gisela","year":"2017","unstructured":"Gisela K, Alan T, Jenny B, Mia G, Jennifer E, the MSG, the European Multiple Sclerosis P (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23:1123\u20131136","journal-title":"Mult Scler"},{"key":"3550_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/00207454.2016.1198793","volume":"127","author":"H Pakdaman","year":"2017","unstructured":"Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Tabassi A, Ashrafi F, Ghaffarpor M, Sharifi S, Delavar Kasmae H, Assarzadegan F (2017) Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon \u03b2-1a in Iran. Int J Neurosci 127:501\u2013507","journal-title":"Int J Neurosci"},{"key":"3550_CR13","first-page":"139","volume":"7","author":"B Najafi","year":"2015","unstructured":"Najafi B, Ghaderi H, Jafari M, Najafi S, Kiadaliri AA (2015) Cost effectiveness analysis of Avonex and CinnoVex in relapsing remitting MS. Glob J Health Sci 7:139","journal-title":"Glob J Health Sci"},{"key":"3550_CR14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.clineuro.2012.02.039","volume":"114","author":"S Nafissi","year":"2012","unstructured":"Nafissi S, Azimi A, Amini-Harandi A, Salami S, Heshmat R (2012) Comparing efficacy and side effects of a weekly intramuscular biogeneric\/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. Clin Neurol Neurosurg 114:986\u2013989","journal-title":"Clin Neurol Neurosurg"},{"key":"3550_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292\u2013302","journal-title":"Ann Neurol"},{"key":"3550_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"3550_CR17","first-page":"3","volume":"13","author":"N Sharafaddinzadeh","year":"2011","unstructured":"Sharafaddinzadeh N, Majdinasab N, Ghiasian M, Moravej-Aleali A (2011) Efficacy of interferon \u03b21a (Cinnovex) in relapsing-remitting multiple sclerosis patients. ZJRMS 13:3\u20136","journal-title":"ZJRMS"},{"key":"3550_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.410430114","volume":"43","author":"JH Simon","year":"1998","unstructured":"Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM (1998) Magnetic resonance studies of intramuscular interferon \u03b2\u20131a for relapsing multiple sclerosis. Ann Neurol 43:79\u201387","journal-title":"Ann Neurol"},{"key":"3550_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"LD Jacobs","year":"2000","unstructured":"Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898\u2013904","journal-title":"N Engl J Med"},{"key":"3550_CR20","first-page":"93","volume":"27","author":"M Etemadifar","year":"2009","unstructured":"Etemadifar M, Maghzi A, HOSSEINZADEH A (2009) Comparing side effects of cinnovex with avonex in relapsing remitting multiple sclerosis patients. JIMS 27:93\u201399","journal-title":"JIMS"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3550-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3550-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:45:34Z","timestamp":1661906734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3550-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3550"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3550-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"29 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}